Stock Comparison

DERM vs JNJ

Journey Medical Corp vs Johnson & Johnson

The Verdict

DERM takes this one.

Winner

DERM

Journey Medical Corp

8.0

out of 10

Hidden Gem

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$165M

Market Cap

$557.1B

3.4

P/E Ratio

26.5

-14.8%

Profit Margin

21.8%

-35.6%

Return on Equity

26.3%

0.8

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

8.0

DVR Score

1.0

The Deep Dive

DERM8.0/10

Journey Medical (DERM) maintains its high-risk, high-reward profile, primarily driven by the upcoming PDUFA decision for DFD-29 in Q3 2026. The Q1 2026 earnings report showed positive signs with a revenue beat ($15.96M vs. $15.47M consensus), 21% YoY growth, narrowing losses (EPS $(0.08)$ vs $(0.18)$ YoY), and positive Adjusted EBITDA of $0.62M. Cash and equivalents also increased to $27.22M, prov...

Full DERM Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.